SOURCE: Wall Street Press Wire

Wall Street Press Wire

April 15, 2008 08:33 ET

Breaking Stock Alert: OCOL

NOTE TO EDITORS: The Following Is an Investment Opinion Being Issued by Wall Street Capital Funding.

MIAMI, FL--(Marketwire - April 15, 2008) - Wall Street Press Wire (www.WallStreetPressWire.com) is please to highlight its "stocks on the move" for Tuesday. Our list includes: Oncolin Therapeutics (OTCBB: OCOL), Schering-Plough Corporation (NYSE: SGP), Allegheny Technologies Incorporated (NYSE: ATI), Merck & Co. (NYSE: MRK).

Having announced it has entered into negotiations with one of the world's leading cancer institutes, Wall Street Press Wire is continuing its in-depth coverage of Oncolin Therapeutics (OTCBB: OCOL), a biopharmaceutical company that engages in the discovery, development and commercialization of novel selective anticancer therapies.

Yesterday after the markets closed, the company issued an important press release announcing that one of its lead drug candidates has shown in preclinical testing that it extends the life of animals that have human tumors implanted in their brains. According to the press release, the early testing has yielded results in animals that are equivalent to that of Temodar®, which is one of the leading cancer treatments for brain cancer with annual revenues in excess of $500 million annually. This technology is covered under Oncolin's recent exclusive option to license from The University of Texas M.D. Anderson.

In further studies it was determined that the administration of a combination of our compound with Temodar® produces superior anti-tumor activity when compared to Temodar® alone, resulting in increased survival.

"Even though these tests are very early stage they have generated some very positive results which validate our theory of this treatment. We are continuing to undertake and complete the preclinical studies required for a goal of beginning a phase I trial by the beginning of 2009," said Dr Donald Picker, President and COO.

OCOL is on the move! Last week, the company reported that it has entered into negotiations with one of the world's leading cancer institutes to commercially develop a new cancer technology. "We are excited about the prospects of this new development program and the opportunity to add to our pipeline of cancer therapeutics," said Dr. Donald Picker, President and COO of the company.

Other recent news that should be of interest of investors includes:

Oncolin Therapeutics Obtains an Exclusive Worldwide Right to Option Patents Covering the Composition and Use of Genistein Analogs for Cancer Treatment

Oncolin has recently announced that is has obtained an exclusive option agreement with the Pharmaceutical Research Institute of Warsaw, Poland which provides the company the right to license the use of Genistein analogs for cancer treatment.

Oncolin Announces Its Research Program Receives Peer Reviewed National Institute of Health Grant of $179,000.

Wall Street Press Wire's in-depth profile for Oncolin Therapeutics is available at: http://www.WallStreetNewsAlert.com/HotStocks/OCOL041409/default.aspx

The stock closed Monday at Forty Two cents a share.

Schering-Plough Corporation (NYSE: SGP) down 3.8% on 16.5 million shares traded. Schering-Plough is an innovation-driven, science-centered global health care company.

Allegheny Technologies Incorporated (NYSE: ATI) down 4% on 2.1 million shares traded. Allegheny Technologies Incorporated is one of the largest and most diversified specialty metals producers in the world with revenues of $5.5 billion during 2007.

Merck & Co. (NYSE: MRK) up 0.6% on 13.5 million shares traded. Merck & Co., Inc. is a global research-driven pharmaceutical company dedicated to putting patients first. Established in 1891, Merck currently discovers, develops, manufacturers and markets vaccines and medicines to address unmet medical needs.

Wall Street Press Wire:

Wall Street Press Wire (WSPW) is the premiere online financial destination of choice for today's investment community, and a leading provider of online press release distribution and a disseminator of electronic information. From Wall Street to Main Street, our goal is to bridge the gap between emerging publicly traded companies and shareholders across the country.

With many small publicly traded companies operating under the radar of mainstream Wall Street, our service places their news story in front of the eyes of the investment community. Utilizing a targeted distribution approach, their story reaches the top news websites on the web and thousands of investors nationwide. For more information on our products, please visit: http://www.wallstreetpresswire.com/content.php?UID=5

Wall Street Press Wire (WSPW) is a division of Wall Street Capital Funding LLC (WSCF). WSCF also maintains a contractual, working relationship with Stock Market Alerts LLC and its Wall Street Enews brand. WSPW is not a registered broker/dealer and may not sell, offer to sell or offer to buy any security. WSPW profiles are not a solicitation or recommendation to buy, sell or hold securities. An offer to buy or sell can be made only with accompanying disclosure documents from the company offering or selling securities and only in the states and provinces for which they are approved. The material in this release is intended to be strictly informational. The companies that are discussed in this release have not approved the statements made in this release nor approved the timing of this release. All statements and expressions are the sole opinion of WSPW and are subject to change without notice. Information in this release is derived from a variety of sources including that company's publicly disseminated information, third parties and WSPW research. The accuracy or completeness of the information is not warranted and is only as reliable as the sources from which it was obtained. WSPW disclaims any and all liability as to the completeness or accuracy of the information contained and any omissions of material fact in this release. The release may contain technical inaccuracies or typographical errors. It is strongly recommended that any purchase or sale decision be discussed with a financial adviser, or a broker-dealer, or a member of any financial regulatory bodies. Investment in the securities of the companies discussed in this release is highly speculative and carries a high degree of risk. WSPW is not liable for any investment decisions by its readers or subscribers. Investors are cautioned that they may lose all or a portion of their investment if they make a purchase in WSPW profiled stocks.

This profile is not without bias, and is a paid release. WSCF has been compensated Nineteen Thousand Dollars for coverage of Oncolin Therapeutics (OTCBB: OCOL), previously known as Edgeline Holdings, Inc., by the company, for services provided including dissemination of company information in this release. Prior to the name and symbol change, WSCF was previously compensated for services rendered in 2008 and 2007; the previous compensation can be viewed by looking at a previous WSNA, ELHI press release. WSCF holds no shares of the stock. WSCF may receive compensation for future services. Any additional compensation will be disclosed at such time that WSCF is aware of a client's desire to begin services. WSCF may have received shares of a company profiled in this release prior to the dissemination of the information in this release. WSCF may immediately sell some or any shares in a profiled company held by WSCF and may have previously sold shares in a profiled company held by WSCF. WSCF's services for a company may cause the company's stock price to increase, in which event WSCF would make a profit when it sells its stock in a company. In addition, WSCF's selling of a company's stock may have a negative effect on the market price of the stock.

This release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. "Forward-looking statements" describe future expectations, plans, results, or strategies and are generally preceded by words such as "may," "future," "plan" or "planned," "will" or "should," "expected," "anticipates," "draft," "eventually" or "projected." You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a companies' annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and WSPW undertakes no obligation to update such statements

Contact Information